A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-Target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes

Trial Profile

A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-Target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Insulin detemir (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EFFICACY
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jun 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
    • 10 Jun 2010 New source identified and integrated (Clinical Trials Registry - India).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top